These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12869471)

  • 1. Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes.
    Nardell EA
    BMJ; 2003 Jul; 327(7407):164; author reply 164. PubMed ID: 12869471
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB).
    Gupta R; Espinal M;
    Int J Tuberc Lung Dis; 2003 May; 7(5):410-4. PubMed ID: 12757039
    [No Abstract]   [Full Text] [Related]  

  • 4. Multi-drug resistant tuberculosis in context of RNTCP.
    Arora VK; Visalakshi P
    Indian J Chest Dis Allied Sci; 2003; 45(3):215-9. PubMed ID: 12866642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
    Ollé-Goig JE; Sandy R
    Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru.
    Mukherjee JS; Joseph JK; Rich ML; Shin SS; Furin JJ; Seung KJ; Sloutsky A; Socci AR; Vanderwarker C; Vasquez L; Palacios E; Guerra D; Viru FA; Farmer P; Del Castillo HE
    Int J Tuberc Lung Dis; 2003 Jul; 7(7):637-44. PubMed ID: 12870684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.
    Laserson KF; Thorpe LE; Leimane V; Weyer K; Mitnick CD; Riekstina V; Zarovska E; Rich ML; Fraser HS; Alarcón E; Cegielski JP; Grzemska M; Gupta R; Espinal M
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):640-5. PubMed ID: 15971391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
    Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
    Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of multidrug-resistant tuberculosis: Update 2007.
    Yew WW; Leung CC
    Respirology; 2008 Jan; 13(1):21-46. PubMed ID: 18197909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-drug resistant tuberculosis: an iatrogenic problem.
    Kant S; Maurya AK; Kushwaha RA; Nag VL; Prasad R
    Biosci Trends; 2010 Apr; 4(2):48-55. PubMed ID: 20448341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis care in 2013 and beyond: 20 years after the birth of the DOTS strategy.
    Seita A
    East Mediterr Health J; 2013 Mar; 19(3):211-2. PubMed ID: 23879070
    [No Abstract]   [Full Text] [Related]  

  • 13. [Impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis patients receiving directly observed treatment strategy in Henan Province, China].
    Wang GJ; Xu JY; Wang GB; Zhen XA; Gao SY; Du CM
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):527-30. PubMed ID: 17074265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
    Van Deun A; Salim MA; Das AP; Bastian I; Portaels F
    Int J Tuberc Lung Dis; 2004 May; 8(5):560-7. PubMed ID: 15137531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.
    Sterling TR; Lehmann HP; Frieden TR
    BMJ; 2003 Mar; 326(7389):574. PubMed ID: 12637401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required?
    Bastian I; Rigouts L; Van Deun A; Portaels F
    Bull World Health Organ; 2000; 78(2):238-51. PubMed ID: 10743297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of directly observed treatment for tuberculosis in Ensenada, Mexico: not all DOTS programs are created equally.
    Radilla-Chávez P; Laniado-Laborín R
    Int J Tuberc Lung Dis; 2007 Mar; 11(3):289-92. PubMed ID: 17352094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond DOtS: avenues ahead in the management of tuberculosis.
    Chaudhury RR; Thatte U
    Natl Med J India; 2003; 16(6):321-7. PubMed ID: 14765625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003.
    Anuradha B; Aparna S; Hari Sai Priya V; Vijaya Lakshmi V; Akbar Y; Suman Latha G; Murthy KJ
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):58-62. PubMed ID: 16466038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.